Eli Lilly

Page 2 of 7

A person stands on a scale.
Health

Hims & Hers Super Bowl ad slams pricey pharma industry—and fumbles FDA warnings on compounded GLP-1 drugs

By
February 3, 2025
The increase in online searches for obesity management drugs in recent years correlated to a surge in dispensed prescriptions, according to a new study from the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease.
Health

Online searches predicted the surge in prescriptions of weight-loss drugs like Wegovy and Zepbound, study says. Here’s what could happen next

By
January 29, 2025
Eli Lilly & Co., the Fortune 500 pharma firm that manufactures weight-loss injection Zepbound (tirzepatide), has a comparable oral medication in the works that could be approved by the FDA as early as 2026, CEO Dave Ricks told Bloomberg TV on Jan. 13, 2025.
Health

Hate needles? Lilly’s weight-loss pill could get FDA approval next year, CEO says

By
January 22, 2025
Arianna Huffington
Newsletters

Exclusive: Arianna Huffington’s Thrive Global inks novel partnership with pharma giant Eli Lilly

By Alexa Mikhail and Nina Ajemian
January 9, 2025
Elon Musk admits he takes an Ozempic-like weight-loss drug that RFK Jr. wants to restrict
Health

Elon Musk admits he takes an Ozempic-like weight-loss drug that RFK Jr. wants to restrict

By
December 27, 2024
Novo Nordisk advertising flags and logo on facade, Danish pharmaceutical healthcare giant Novo Nordisk AS, production innovative drugs, obesity treatment Ozempic, Mainz, Germany June 15, 2024
Health

Novo Nordisk faces stock market bloodbath after weight-loss drug trial disappoints

By Ryan Hogg and AFP
December 20, 2024
Close-up of a patient administering a dose of Zepbound (tirzepatide)
Health

Zepbound vs. Wegovy: New clinical trial says this weight-loss medication sheds more pounds

By
December 4, 2024
Novo Nordisk’s Wegovy sales jump on international rollouts
Retail

Novo Nordisk’s Wegovy sales jump on international rollouts

By Naomi Kresge and Bloomberg
November 6, 2024
Alphabet CEO Sundar Pichai moves his hands as he talks during an interview
Finance

Over 25% of Google’s code is now written by AI—and CEO Sundar Pichai says it’s just the start

By
October 30, 2024
Despite the ubiquitousness of injectable GLP-1 drugs indicated for people with obesity, most Americans wouldn’t take them, according to a September 2024 survey from the Physicians Committee for Responsible Medicine.
Health

Most Americans who want to lose weight don’t want to take GLP-1 drugs like Wegovy and Zepbound, new survey says

By
October 10, 2024
Tesla CEO Elon Musk attends the 10th Annual Breakthrough Prize Ceremony at Academy Museum of Motion Pictures.
Health

Elon Musk and Bernie Sanders say they agree on one thing—cheaper Ozempic

By
September 25, 2024
Roche stock is falling after report its Wegovy challenger is causing patients to vomit
Health

Roche stock is falling after report its Wegovy challenger is causing patients to vomit

By Naomi Kresge and Bloomberg
September 12, 2024
Eli Lilly’s new CFO is a 23-year company veteran—showing how pharma firms rely on a ‘deep bench of qualified talent’
Newsletters

Eli Lilly’s new CFO is a 23-year company veteran—showing how pharma firms rely on a ‘deep bench of qualified talent’

By
September 10, 2024
In this year’s Global 500 list: Energy woes, retail gains, and boom times for AI and weight-loss drugs
Newsletters

In this year’s Global 500 list: Energy woes, retail gains, and boom times for AI and weight-loss drugs

By
August 5, 2024

Most Popular